Haemonetics Corp (NYSE: HAE) grants 2,538 RSUs to board director

Rhea-AI Filing Summary

Pomeroy Claire reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Claire Pomeroy reported a grant of 2,538 restricted stock units (RSUs) under the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan on 2026-07-24. The RSUs vest 100% on the first anniversary of the grant date, with each RSU delivering one share of common stock upon vesting. After this award, her direct holdings total 19,410 shares of common stock.

Insider Trade Summary

Net Buyer: 2,538 shares

Net Buy 1 txn

Insider Pomeroy Claire

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	2,538	--	--

Holdings After Transaction: Common Stock — 19,410 shares (Direct)

Footnotes (2)

1. F1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
2. F2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

Key Figures

RSUs granted: 2,538 shares Shares following transaction: 19,410 shares Vesting schedule: 100% after 1 year +1 more

4 metrics

RSUs granted 2,538 shares Restricted stock units granted to director Claire Pomeroy on 2026-07-24

Shares following transaction 19,410 shares Total direct common stock holdings after the reported RSU award

Vesting schedule 100% after 1 year RSUs vest 100% on the first anniversary of the grant date

RSU-to-share ratio 1 RSU = 1 share Each RSU represents a contingent right to receive one share of common stock when vested

Key Terms

restricted stock units, Amended and Restated 2019 Long-Term Incentive Compensation Plan, contingent right

3 terms

restricted stock units financial

"The securities awarded are in the form of restricted stock units ("RSUs") issued"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Amended and Restated 2019 Long-Term Incentive Compensation Plan financial

"issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan"

contingent right financial

"Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/28/2026 - 05:01 PM Accepted by SEC EDGAR 07/28/2026 - 05:00 PM Learn about SEC filing dates

FAQ

What insider transaction did Haemonetics (HAE) report for director Claire Pomeroy?

Haemonetics reported a grant of 2,538 restricted stock units (RSUs) to director Claire Pomeroy on 2026-07-24. These RSUs are part of the company’s Amended and Restated 2019 Long-Term Incentive Compensation Plan and convert into common shares when vested.

When do the 2,538 RSUs granted to the Haemonetics (HAE) director vest?

The 2,538 RSUs vest 100% on the first anniversary of the grant date. This means all units cliff-vest one year after 2026-07-24, at which time they become payable in shares of Haemonetics common stock, subject to the plan’s terms.

How many Haemonetics (HAE) shares does Claire Pomeroy hold after this RSU award?

Following the reported grant, Claire Pomeroy directly holds 19,410 shares of Haemonetics common stock. This total reflects her position after the acquisition of 2,538 RSUs, which each represent a right to receive one share upon vesting.

What does each restricted stock unit (RSU) represent in the Haemonetics (HAE) grant?

Each RSU in this grant represents a contingent right to receive one share of Haemonetics common stock. When the RSUs vest after one year, they are settled in an equivalent number of common shares, according to the plan’s provisions.

Under which equity plan were the 2,538 RSUs granted at Haemonetics (HAE)?

The 2,538 RSUs were issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. This plan governs the award’s terms, including vesting, settlement into common shares, and other compensation-related conditions for participants.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pomeroy Claire

(Last) (First) (Middle)

125 SUMMER STREET

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
HAEMONETICS CORP [ HAE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/24/2026		A		2,538(1)	A	(2)	19,410	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.

2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.

	/s/ Thomas V. Powers, attorney-in-fact for Dr. Pomeroy	07/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)